HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.5%

Neg 0% Neu 90.5% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.